Immunotherapy: the next step in the treatment of myeloma
Mené sur 73 patients atteints d'un myélome multiple récidivant, cet essai randomisé international de phase II évalue l'efficacité, du point de vue du taux de réponse objective, et la toxicité de l'ajout d'élotuzumab à un traitement combinant lénalidomide et dexaméthasone
An improved understanding of the molecular pathways involved in cancer development has enabled the rational design of drugs that target and selectively interfere with oncogenic signalling pathways, thus moving from the one size fits all approach to a more personalised therapy. As a result, cancers, including multiple myeloma, are now treated effectively, with prolonged survival. Nevertheless, nearly all patients with myeloma will have acquired resistance arising from several changes, such as gene mutations, amplification, or alternative splicing, and different mechanisms might be in operation in different cells because of intratumour heterogeneity.